Cargando…

A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. However, the efficacy of EGFR-TKIs in wild-type (wt) EGFR tumours has been shown to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Duo, Zhou, Jun, Fang, Weimin, Huang, Cuiqing, Chen, Zerong, Fan, Meng, Zhang, Ming-Rong, Xiao, Zeyu, Hu, Kuan, Luo, Liangping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	KeAi Publishing 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844835/ https://www.ncbi.nlm.nih.gov/pubmed/35224311 http://dx.doi.org/10.1016/j.bioactmat.2021.10.046

Ejemplares similares

Interference With Redox Homeostasis Through a G6PD-Targeting Self-Assembled Hydrogel for the Enhancement of Sonodynamic Therapy in Breast Cancer
por: Huang, Cuiqing, et al.
Publicado: (2022)

Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment
por: Xue, Xiangdong, et al.
Publicado: (2018)

PEIGel: A biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy
por: Xiao, Zeyu, et al.
Publicado: (2022)

Review of the Application of Dual Drug Delivery Nanotheranostic Agents in the Diagnosis and Treatment of Liver Cancer
por: Han, Qinghe, et al.
Publicado: (2023)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Ceria-based nanotheranostic agent for rheumatoid arthritis
por: Kalashnikova, Irina, et al.
Publicado: (2020)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
por: Polychronidou, Genovefa, et al.
Publicado: (2013)

Self-assembled multifunctional nanotheranostics against circulating tumor clusters in metastatic breast cancer
por: Dhandapani, Ramya, et al.
Publicado: (2023)

Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
por: Ma, Xiaocong, et al.
Publicado: (2023)

Cancer nanotheranostics
por: Gopinath, P, et al.
Publicado: (2015)

Introduction to nanotheranostics
por: Tamil Selvan, Subramanian, et al.
Publicado: (2016)

Supramolecular Nanotheranostics
por: Chen, Xiaoyuan, et al.
Publicado: (2019)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
por: Zhou, Xin, et al.
Publicado: (2021)

Nanotheranostics for cancer applications
por: Rai, Prakash, et al.
Publicado: (2018)

MXenes in Cancer Nanotheranostics
por: Iravani, Siavash, et al.
Publicado: (2022)

A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer
por: Minemura, Hiroyuki, et al.
Publicado: (2015)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

Multifunctional Nanotheranostic Gold Nanocage/Selenium Core-Shell for PAI-Guided Chemo-Photothermal Synergistic Therapy in vivo
por: Fang, Xueyang, et al.
Publicado: (2020)

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023)

Progress in the Development of Nanotheranostic Systems
por: Cui, Honggang, et al.
Publicado: (2016)

Multimodality imaging in nanomedicine and nanotheranostics
por: Li, Xue, et al.
Publicado: (2016)

Supramolecular nanotheranostics based on pillarenes
por: Song, Nan, et al.
Publicado: (2019)

Nanotheranostics Targeting the Tumor Microenvironment
por: Roma-Rodrigues, Catarina, et al.
Publicado: (2019)

Targeted Magnetic Nanotheranostics of Cancer
por: Belyanina, Irina, et al.
Publicado: (2017)

Interventional nanotheranostics in hepatocellular carcinoma
por: Chavda, Vivek P., et al.
Publicado: (2023)

Recent Advances in Nanotheranostic Agents for Tumor Microenvironment–Responsive Magnetic Resonance Imaging
por: Jin, Longhai, et al.
Publicado: (2022)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer
por: Moecks, Joachim, et al.
Publicado: (2015)

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial
por: Neal, Joel W., et al.
Publicado: (2016)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Diagnostic Performance of Perfusion Computed Tomography for Differentiating Lung Cancer from Benign Lesions: A Meta-Analysis
por: Huang, Cuiqing, et al.
Publicado: (2019)

Fluorescent Silicon Nanorods-Based Nanotheranostic Agents for Multimodal Imaging-Guided Photothermal Therapy
por: Cui, Mingyue, et al.
Publicado: (2019)

Nanotheranostics – a review of recent publications
por: Wang, Li-Sheng, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_742rj7hh4tnrkle95qa08p3mlg